We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.
- Authors
Ballotta, Laura; Zinzani, Pier Luigi; Pileri, Stefano; Bruna, Riccardo; Tani, Monica; Casadei, Beatrice; Tabanelli, Valentina; Volpetti, Stefano; Luminari, Stefano; Corradini, Paolo; Lucchini, Elisa; Tisi, Maria Chiara; Merli, Michele; Re, Alessandro; Varettoni, Marzia; Pesce, Emanuela Anna; Zaja, Francesco
- Abstract
Patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) have a poor prognosis, with an expected survival of less than 1 year using standard salvage therapies. Recent advances in our understanding of the biology of PTCL have led to identifying B-Cell Lymphoma 2 (BCL2) protein as a potential therapeutic target. BLC2 inhibitor venetoclax was investigated in a prospective phase II trial in patients with BCL2-positive R/R PTCL after at least one previous standard line of treatment (NCT03552692). Venetoclax given alone at a dosage of 800 mg/day resulted in one complete response (CR) and two stable diseases (SDs) among 17 enrolled patients. The majority of patients (88.2%) interrupted the treatment due to disease progression. No relationship with BCL2 expression was documented. At a median follow-up of 8 months, two patients are currently still on treatment (one CR and one SD). No case of tumor lysis syndrome was registered. Therefore, venetoclax monotherapy shows activity in a minority of patients whose biological characteristics have not yet been identified. Clinical Trial Registration: www.clinicaltrials.gov (NCT03552692, EudraCT number 2017-004630-29).
- Subjects
T-cell lymphoma; VENETOCLAX; TUMOR lysis syndrome; PROGNOSIS; MANTLE cell lymphoma; THERAPEUTICS
- Publication
Frontiers in Oncology, 2021, Vol 11, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2021.789891